Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324424 | PMC |
| http://dx.doi.org/10.1055/s-0041-1732340 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Heparin-azithromycin microparticles show anti-inflammatory effects and inhibit SARS-CoV-2 and bacterial pathogens associated to lung infections.
Carbohydr Polym
January 2025
Pharmaceutics and Food Technology Department, Faculty of Pharmacy, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain; Instituto Universitario de Farmacia Industrial, Faculty of Pharmacy, Universidad Complutense de Madrid, 28040 Madrid, Spain. Electronic address:
Pulmonary infections are a leading cause of morbidity and mortality worldwide, a situation exacerbated by the COVID-19. Azithromycin (AZM) is used orally to treat pulmonary infections due to its ability to accumulate in lung tissues and immune cells after oral administration. Sulfated polysaccharides, such as heparin, are known to inhibit SARS-CoV-2 entry.
View Article and Find Full Text PDF"To BAL or not to BAL, that is the question": Variations in smoke inhalation injury guidelines from burn units and centres in England, Scotland and Wales.
Burns
December 2024
Department of Burns and Plastic Surgery, Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust, United Kingdom. Electronic address:
Aim: To evaluate variations in diagnostic criteria and management recommendations for smoke inhalation injury (SII) amongst the burn networks of England, Scotland, and Wales.
Methods: A descriptive cross-sectional study examining SII guidelines provided by adult burn units and centres in England, Scotland and Wales.
Results: All 16 adult burn units and centres responded.
Nebulized enriched heparin improves respiratory parameters in patients with COVID-19: a phase I/II randomized and triple-blind clinical trial.
Sci Rep
August 2024
Department of Infectious Diseases, Botucatu Medical School, São Paulo State University - UNESP, Botucatu, SP, Brazil.
To evaluate the safety and the potential antiviral treatment of inhaled enriched heparin in patients with COVID-19. The specific objectives were to investigate the anticoagulation profile, antiviral and anti-inflammatory effects, and respiratory evolution of inhaled enriched heparin. We conducted a randomized, triple-blind, placebo-controlled Phase I/II clinical trial in hospitalized adults with COVID-19 receiving inhalation of enriched heparin or saline (placebo) every 4 h for 7 days.
View Article and Find Full Text PDFFugitive medical and patient-derived aerosol particle distribution following heparin nebulization in patients with COVID-19 acute hypoxemic respiratory failure: a secondary analysis of the CHARTER study.
Intensive Care Med Exp
August 2024
Department of Anaesthesia and Intensive Care Medicine, University Hospital Galway, Newcastle Road, Galway, H91 YR71, Ireland.
The Efficacy of Daily Administration of Nebulized Heparin on the Prevention of Endotracheal Tube Blockage in Patients With Pneumonia.
Cureus
January 2024
Department of Internal Medicine, School of Medicine, Air Pollution and Respiratory Diseases Research Center, Imam Khomeini Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IRN.
Objective: Nosocomial infections pose a significant public health concern, impacting over 100 million people worldwide annually. Within this research, we investigated heparin nebulization through the endotracheal tube and its effect on preventing blockage due to clots and mucus plugs compared to normal saline.
Methods: A double-blind clinical experiment was done on a cohort of 40 pneumonia patients who were intubated and hospitalized in the intensive care unit (ICU) at Imam Khomeini Hospital in Ahvaz, Iran.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!